GAN
Basic information
Region (hg38): 16:81314944-81390884
Links
Phenotypes
GenCC
Source:
- giant axonal neuropathy 1 (Supportive), mode of inheritance: AR
- giant axonal neuropathy 1 (Strong), mode of inheritance: AR
- giant axonal neuropathy 1 (Definitive), mode of inheritance: AR
Clinical Genomic Database
Source:
Condition | Inheritance | Intervention Categories | Intervention/Rationale | Manifestation Categories | References |
---|---|---|---|---|---|
Giant axonal neuropathy 1, autosomal recessive | AR | General | Genetic knowledge may be beneficial related to issues such as selection of optimal supportive care, informed medical decision-making, prognostic considerations, and avoidance of unnecessary testing | Dermatologic; Musculoskeletal; Neurologic | 11062483; 11053687; 18595793; 19231187; 20301315; 20949505; 21356581 |
ClinVar
This is a list of variants' phenotypes submitted to
- Giant axonal neuropathy 1 (24 variants)
- Inborn genetic diseases (2 variants)
- not provided (1 variants)
Variants pathogenicity by type
Statistics on ClinVar variants can assist in determining whether a specific variant type in the GAN gene is commonly pathogenic or not.
In the table, we include only reliable ClinVar variants with their consequences to MANE Select, Mane Plus Clinical transcripts, or transcripts with TSL equals 1. Click the count to view the source variants.
Warning: slight differences between displayed counts and the number of variants in ClinVar may occur, primarily due to (1) the application of a different transcript and/or consequence by our variant effect predictor or (2) differences in clinical significance: we classify Benign/Likely benign variants as Likely benign and Pathogenic/Likely pathogenic variants as Likely pathogenic.
Variant type | Pathogenic | Likely pathogenic | VUS | Likely benign | Benign | Sum |
---|---|---|---|---|---|---|
synonymous | 145 | 152 | ||||
missense | 286 | 292 | ||||
nonsense | 14 | 18 | ||||
start loss | 0 | |||||
frameshift | 10 | 14 | ||||
inframe indel | 2 | |||||
splice donor/acceptor (+/-2bp) | 9 | |||||
splice region | 16 | 11 | 1 | 28 | ||
non coding | 47 | 83 | 51 | 181 | ||
Total | 27 | 15 | 344 | 229 | 53 |
Highest pathogenic variant AF is 0.00000658
Variants in GAN
This is a list of pathogenic ClinVar variants found in the GAN region.
You can filter this list by clicking the number of variants in the Variants pathogenicity by type table.
Position | Type | Phenotype | Significance | ClinVar |
---|---|---|---|---|
16-81314987-C-T | Giant axonal neuropathy 1 | Uncertain significance (Jan 13, 2018) | ||
16-81314988-T-C | Giant axonal neuropathy 1 | Uncertain significance (Jan 13, 2018) | ||
16-81315003-G-A | Giant axonal neuropathy 1 | Uncertain significance (Jan 13, 2018) | ||
16-81315039-G-C | Giant axonal neuropathy 1 | Benign (Jun 20, 2018) | ||
16-81315040-G-C | Giant axonal neuropathy 1 | Uncertain significance (Jan 12, 2018) | ||
16-81315044-C-T | Giant axonal neuropathy 1 | Uncertain significance (Jan 12, 2018) | ||
16-81315067-G-A | not specified | Likely benign (Jun 12, 2017) | ||
16-81315099-G-C | Giant axonal neuropathy 1 | Uncertain significance (Apr 27, 2017) | ||
16-81315117-G-A | Giant axonal neuropathy 1 | Uncertain significance (Sep 02, 2021) | ||
16-81315119-T-G | Giant axonal neuropathy 1 | Likely benign (Nov 06, 2023) | ||
16-81315122-G-A | Giant axonal neuropathy 1 | Likely benign (Apr 04, 2022) | ||
16-81315123-G-A | Giant axonal neuropathy 1 | Uncertain significance (Feb 25, 2021) | ||
16-81315126-A-C | Uncertain significance (Feb 01, 2022) | |||
16-81315127-G-A | Giant axonal neuropathy 1 | Uncertain significance (Jul 26, 2020) | ||
16-81315127-G-C | Giant axonal neuropathy 1 | Uncertain significance (Oct 08, 2020) | ||
16-81315130-C-T | Giant axonal neuropathy 1 | Uncertain significance (Feb 03, 2022) | ||
16-81315130-CCGTGTCTGACCCTCAGCACGCCGCGCGTCTGCTGCGAG-C | Giant axonal neuropathy 1 | Uncertain significance (Jan 06, 2016) | ||
16-81315131-C-T | Giant axonal neuropathy 1 | Likely benign (Feb 21, 2023) | ||
16-81315131-C-CA | Giant axonal neuropathy 1 | Conflicting classifications of pathogenicity (Jan 06, 2016) | ||
16-81315136-C-G | Charcot-Marie-Tooth disease • Giant axonal neuropathy 1 | Uncertain significance (May 01, 2022) | ||
16-81315138-G-T | Giant axonal neuropathy 1 | Uncertain significance (Dec 02, 2021) | ||
16-81315140-C-G | Giant axonal neuropathy 1 | Uncertain significance (Jun 14, 2023) | ||
16-81315140-C-T | Giant axonal neuropathy 1 | Likely benign (Jul 13, 2023) | ||
16-81315141-C-T | Giant axonal neuropathy 1 | Uncertain significance (Jun 30, 2023) | ||
16-81315142-C-G | Giant axonal neuropathy 1 | Uncertain significance (Jul 12, 2022) |
GnomAD
Source:
Gene | Type | Bio Type | Transcript | Coding Exons | Length |
---|---|---|---|---|---|
GAN | protein_coding | protein_coding | ENST00000568107 | 11 | 75933 |
pLI Probability LOF Intolerant | pRec Probability LOF Recessive | Individuals with no LOFs | Individuals with Homozygous LOFs | Individuals with Heterozygous LOFs | Defined | p |
---|---|---|---|---|---|---|
0.0248 | 0.975 | 125714 | 0 | 34 | 125748 | 0.000135 |
Z-Score | Observed | Expected | Observed/Expected | Mutation Rate | Total Possible in Transcript | |
---|---|---|---|---|---|---|
Missense | -0.726 | 367 | 330 | 1.11 | 0.0000201 | 3909 |
Missense in Polyphen | 64 | 76.897 | 0.83228 | 908 | ||
Synonymous | -4.75 | 189 | 122 | 1.55 | 0.00000812 | 1130 |
Loss of Function | 3.71 | 9 | 31.4 | 0.286 | 0.00000181 | 369 |
LoF frequencies by population
Ethnicity | Sum of pLOFs | p |
---|---|---|
African & African-American | 0.000468 | 0.000468 |
Ashkenazi Jewish | 0.00 | 0.00 |
East Asian | 0.00 | 0.00 |
Finnish | 0.000139 | 0.000139 |
European (Non-Finnish) | 0.000132 | 0.000123 |
Middle Eastern | 0.00 | 0.00 |
South Asian | 0.0000327 | 0.0000327 |
Other | 0.00 | 0.00 |
dbNSFP
Source:
- Function
- FUNCTION: Probable cytoskeletal component that directly or indirectly plays an important role in neurofilament architecture. May act as a substrate-specific adapter of an E3 ubiquitin-protein ligase complex which mediates the ubiquitination and subsequent proteasomal degradation of target proteins. Controls degradation of TBCB. Controls degradation of MAP1B and MAP1S, and is critical for neuronal maintenance and survival. {ECO:0000269|PubMed:12147674, ECO:0000269|PubMed:15983046, ECO:0000269|PubMed:16227972, ECO:0000269|PubMed:16303566}.;
- Disease
- DISEASE: Giant axonal neuropathy 1, autosomal recessive (GAN1) [MIM:256850]: A severe autosomal recessive sensorimotor neuropathy affecting both the peripheral nerves and the central nervous system. Axonal loss and the presence of giant axonal swellings filled with neurofilaments on nerve biopsies are the hallmarks of this neurodegenerative disorder. {ECO:0000269|PubMed:11062483, ECO:0000269|PubMed:11971098, ECO:0000269|PubMed:12655563, ECO:0000269|PubMed:16303566, ECO:0000269|PubMed:17578852, ECO:0000269|PubMed:17587580}. Note=The disease is caused by mutations affecting the gene represented in this entry.;
- Pathway
- Post-translational protein modification;Metabolism of proteins;Immune System;Adaptive Immune System;Antigen processing: Ubiquitination & Proteasome degradation;Class I MHC mediated antigen processing & presentation;Neddylation
(Consensus)
Recessive Scores
- pRec
- 0.281
Intolerance Scores
- loftool
- 0.353
- rvis_EVS
- -0.6
- rvis_percentile_EVS
- 18.14
Haploinsufficiency Scores
- pHI
- 0.246
- hipred
- N
- hipred_score
- 0.492
- ghis
Essentials
- essential_gene_CRISPR
- N
- essential_gene_CRISPR2
- N
- essential_gene_gene_trap
- gene_indispensability_pred
- E
- gene_indispensability_score
- 0.720
Gene Damage Prediction
All | Recessive | Dominant | |
---|---|---|---|
Mendelian | Medium | Medium | Medium |
Primary Immunodeficiency | Medium | Medium | Medium |
Cancer | Medium | Medium | Medium |
Mouse Genome Informatics
- Gene name
- Gan
- Phenotype
- nervous system phenotype (the observable morphological and physiological characteristics of the extensive, intricate network of electochemical structures in the body that is comprised of the brain, spinal cord, nerves, ganglia and parts of the receptor organs that are manifested through development and lifespan); behavior/neurological phenotype (the observable actions or reactions of mammalian organisms that are manifested through development and lifespan); growth/size/body region phenotype; mortality/aging (the observable characteristics related to the ability of a mammalian organism to live and age that are manifested throughout development and life span); muscle phenotype; cellular phenotype;
Gene ontology
- Biological process
- cytoskeleton organization;protein ubiquitination;post-translational protein modification
- Cellular component
- cytoplasm;cytosol;cytoskeleton;Cul3-RING ubiquitin ligase complex
- Molecular function
- molecular_function;protein binding